WillItSurvive
No grouping · acquisition pending · Malaysia

I Bella Perfect Inc.

Runs 3 aesthetic medical clinics in Malaysia, filed for a small Nasdaq IPO.

Little protection left
Assessed 29 July 2026 · Evidence as of 29 July 2026
Not much stands between this business and its pressures.
On the recordSince 29 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: IPO pricing and Nasdaq listing, unscheduled seven months after F-1 filing
The call

A small, profitable clinic chain trying to become a Nasdaq micro-cap, with a bigger local rival already ahead in branch count and no listing date yet set.

I Bella Perfect runs three medical beauty clinics in Malaysia and makes real money, about $1.35 million in annual profit on $5 million in sales. However, any doctor with a license and a building can start the same business, and competitors like Premier Clinic already have five locations and more scale. The company is trying to go public on Nasdaq, but the process has stalled for seven months and the whole beauty-clinic industry faces uncertainty after a government scandal about doctors renting their names to unlicensed clinics, which could trigger stricter rules that hurt everyone equally.

Why
01
AI pressure: None apparent. This is in-person cosmetic treatment by licensed physicians, AI diagnostics or chatbots do not replace the clinic visit. Could AI do the core job? Only partly.
02
Bigger players: Premier Clinic. Premier Clinic already runs 5 branches in Malaysia, more than I Bella's 3, with no license or technology barrier stopping others from copying the model. Could a giant copy it? Yes, easily.
03
What protects it. Three licensed LCP-certified physicians and existing clinic leases give a small head start, but nothing stops a competitor from hiring similar doctors and opening nearby.
What would change this call
Whether I Bella's Nasdaq IPO prices by Q4 2026 and at what share price versus the $4-6 range. Shows whether investors see any durable advantage or just a thin-float speculative listing.
Any Ministry of Health enforcement action tied to the March 2026 credential-renting scandal. Would reveal sector-wide regulatory risk hitting I Bella's licensing and operations.
Whether Premier Clinic or other rivals open new branches in Kuala Lumpur, Selangor, or Johor within the year. Would show larger competitors directly contesting I Bella's three home markets.
Key numbers
  • TTM revenue $4.20M, up 22.7% (2026-07-15)
  • LTM net income $1.35M on $5.08M revenue (2026-03-09)
  • IPO raise target doubled to ~$19M, shares $4-6 (2026-03-09)
Named risks
  • Nasdaq IPO unpriced for over 7 months after Dec 30 2025 F-1 filing. Severity: high
  • Sector-wide credential-renting scandal (March 2026) may trigger MOH enforcement. Severity: high
  • Fragmented market with larger rival Premier Clinic already at 5 branches. Severity: medium
  • Thin-float, low-coverage micro-cap underwritten by boutique Cathay Securities. Severity: medium
  • Conflicting, unaudited revenue and net income figures across financial trackers. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Premier Cliniclosing to5 branches vs Bella's 3 clinics, established regional scale as of June 2026
MyCliniccontestingNamed as direct competitor in I Bella Perfect's own F-1 filing, Dec 2025
Anggun CliniccontestingNamed as direct competitor in I Bella Perfect's own F-1 filing, Dec 2025
RX CliniccontestingNamed as direct competitor in I Bella Perfect's own F-1 filing, Dec 2025
Unlicensed beauty centerslosing toUndercut licensed clinics on price, per F-1 filing, Dec 2025
Questions people ask
Is I Bella Perfect profitable?
Yes. I Bella Perfect reported LTM net income of $1.35 million on $5.08 million revenue as of March 9, 2026, with a gross margin around 72 percent, according to IPOScoop's March 2026 filing summary.
When will I Bella Perfect's IPO price on Nasdaq?
Unclear. I Bella Perfect filed its F-1 on Dec 30, 2025 and doubled its raise target to about $18.75-19 million via an F-1/A on March 10, 2026, but as of July 15, 2026 the deal still had not priced and no trading date was set.
Who is I Bella Perfect's biggest competitor?
Premier Clinic is the closest scale peer, operating 5 branches across Kuala Lumpur and Selangor versus Bella Clinic's 3 locations, per an aesthetics industry directory dated June 29, 2026. I Bella Perfect's own F-1 also names MyClinic, Anggun Clinic, and RX Clinic as competitors.
Could AI replace I Bella Perfect's clinics?
No. Core procedures like Botox and dermal filler injections must legally be performed by MOH-licensed physicians under Malaysia's Poisons Act 1952, per a March 1, 2026 investigative report, so AI cannot administer these treatments; this protection is industry-wide, not unique to I Bella Perfect.
Is it risky to invest in or join I Bella Perfect right now?
Yes, notably so. Its Nasdaq IPO has sat unpriced for over 7 months since the Dec 30, 2025 filing, and the Malaysian aesthetic-clinic sector faced a credential-renting scandal reported March 1, 2026, raising regulatory enforcement risk across all operators.
Who owns I Bella Perfect?
I Bella Perfect Inc. is a BVI-incorporated holding company founded by CEO Yen Tsing Then, who has run the Bella Clinic business since 2013, with Malaysian operating subsidiaries IBI and IBSA; it is currently founder-owned pending its Nasdaq IPO.
Timeline
  • 2026-07-15IPO still unpriced, trading date TBA per stock tracker
  • 2026-03-10Filed F-1/A doubling offering to 3.75M shares, ~$18.75-19M target
  • 2026-03-09Reported ~$5.08M LTM revenue and $1.35M net income
  • 2026-03-01Investigative report exposed RM40,000 doctor-credential renting in sector
  • 2025-12-30Filed F-1 with SEC for Nasdaq listing under ticker IBL
  • 2025-12-29Set initial IPO terms: 1.875M shares at $4-6, ~$9M target
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Optimum CommunicationsWarner Bros. DiscoveryInflection AI
More companies little protection left →
Sources